Feasible predictive biomarkers for tumor response to mTOR inhibitors, as are already explained in glioblastoma, breast and prostate cancer cells, will be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Consequently, this details is based on preclinical assays, according to in vitro cultured tumor cell lines, which https://caroln429ejn3.madmouseblog.com/profile